33769-07-2

Basic information

• Product Name: 1-TRITYL-1H-IMIDAZOLE-4-METHANOL
• Synonyms: RARECHEM AL BD 0931;4-HYDROXYMETHYL-1H-TRITYLIMIDAZOLE;1-TRITYL-IMIDOZOLE-4-METHANOL;1-TRITYL-1H-IMIDAZOLE-4-METHANOL;(1-TRITYL-1H-IMIDAZOL-4-YL)-METHANOL;4-(Hydroxymethyl)-1-trityl-1H-imidazole;1-(Triphenylmethyl)-4-(hydroxymethyl)imidazole;1-Triphenylmethyl-1H-imidazole-4-methanol
• CAS NO: 33769-07-2
• Molecular Formula: C₂₃H₂₀N₂O
• Molecular Weight: 340.42
• Product Categories: blocks;Imidazoles
• Mol File: 33769-07-2.mol

Chemical Properties

• Melting Point: 226-232
• Boiling Point: 516.1 °C at 760 mmHg
• Flash Point: 265.9 °C
• Appearance: /
• Density: 1.1 g/cm³
• Vapor Pressure: 1.77E-11mmHg at 25°C
• Refractive Index: 1.612
• PKA: 13.61±0.10(Predicted)
• CAS DataBase Reference: 1-TRITYL-1H-IMIDAZOLE-4-METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: 1-TRITYL-1H-IMIDAZOLE-4-METHANOL(33769-07-2)
• EPA Substance Registry System: 1-TRITYL-1H-IMIDAZOLE-4-METHANOL(33769-07-2)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 33769-07-2(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
1-TRITYL-1H-IMIDAZOLE-4-METHANOL is used as a building block for the synthesis of various drugs and bioactive molecules, due to its capacity to form carbon-carbon and carbon-nitrogen bonds, which are essential in creating complex organic compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 1-TRITYL-1H-IMIDAZOLE-4-METHANOL is utilized as a versatile reagent for the development of new drugs, given its role in the formation of crucial chemical bonds that are integral to the structure and function of many pharmaceutical agents.
Used in Medicinal Chemistry:
1-TRITYL-1H-IMIDAZOLE-4-METHANOL is studied for its potential therapeutic applications in the treatment of various diseases and disorders, highlighting its significance in advancing the discovery and design of novel therapeutic agents.

InChI:InChI=1/C23H20N2O/c26-17-22-16-25(18-24-22)23(19-10-4-1-5-11-19,20-12-6-2-7-13-20)21-14-8-3-9-15-21/h1-16,18,26H,17H2

Upstream product

• 28697-53-2 D-arabinopyranose 
• 3473-63-0 formamidine acetic acid 
• 76-83-5 trityl chloride 
• 53525-60-3 4-carbethoxy-1-triphenyl methyl-1H-imidazole 
• 822-55-9 (1H-imidazol-4-yl)methanol 
• 822-55-9 1H-imidazole-5-methanol 
• 32673-41-9 4-hydroxymethyl-1H-imidazole hydrochloride 
• 121-44-8 triethylamine 
• 76074-88-9 methyl 1-(triphenylmethyl)-1H-imidazole-4-carboxylate 
• 32673-41-9 1H-imidazol-5-ylmethanol hydrochloride 

Downstream Products

• 351019-69-7 (E)-N-{5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)-6-[1-(triphenylmethyl)imidazol-4-yl-methoxy]-pyrimidin-4-yl}-2-phenylethenesulfonamide 
• 183500-34-7 4-acetoxymethyl-1-trityl-1H-imidazole 
• 127056-57-9 4-(tert-butyldimethylsilyloxymethyl)-1-(triphenylmethyl)imidazole 
• 1147133-30-9 C₃₀H₂₃N₃O₅ 
• 497856-18-5 4-[[(1-trityl-1H-imidazol-4-yl)methyl]thio]aniline 
• 473659-21-1 diethyl (1-tritylimidazol-4-yl)methylphosphonate 

Relevant articles and documents

Targeting GRP receptor: Design, synthesis and preliminary biological characterization of new non-peptide antagonists of bombesin

We report the rational design, synthesis, and in vitro preliminary evaluation of a new small library of non-peptide ligands of Gastrin Releasing Peptide Receptor (GRP-R), able to antagonize its natural ligand bombesin (BN) in the nanomolar range of concen

ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE

The present invention relates to compounds of formula (I)-(VI) and/or (A)-(H-I), or any subgenera thereof, or a pharmaceutically acceptable salt, tautomer or stereoisomer. The compounds of the present disclosure are useful in modulating androgen receptor activity and for treating cancer including prostate cancer.

HETEROARYL RHEB INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same. Compositions comprising a compound of this invention or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier, adjuvant, or vehicle. The amount of the compound in compositions of this invention is such that it is effective to measurably inhibit Rheb, in a biological sample or in a patient.

Synthesis and antiproliferatory activity of ruthenium complexes containing N-heterocyclic carboxylates

Solvates of the complexes Ru2Cl(pic)4(EtOH) (2), Ru(Im-CO2)3 (3), and Ru(Im-CO2)(Im-CO2H)Cl2 (4), were synthesized from reaction of RuCl3·3H2O or K3[RuCl6] with the N-heterocyclic carboxylic acids pyridine-2-carboxylic acid (picolinic acid, Hpic), and imidazole-4-carboxylic acid (Im-CO2H). Crystals of 2–4 could not be grown and hence characterization was done by elemental analysis, NMR, IR, and conductivity data; 2 and 4 were tested for antiproliferatory activity in vitro against a human breast cancer cell line, but were less active than, for example, Ru complexes containing bis-imidazole or 4,4′-biimidazole that we studied previously [see Can. J. Chem. 89 (2011) 948]. Preliminary work with a third potential ligand, 3-nitro-1,2,4-triazole-5-carboxylic acid (abbreviated HCANT), and other nitro heterocyclic compounds is also presented.

BICYCLIC LACTAMS AND METHODS OF USE THEREOF

The invention provides novel compounds having the general formula I: (I) wherein R1, X, Z1, L, n, the A ring, the B ring, and the C ring are as described herein, pharmaceutical compositions including the compounds and methods of using the compounds.

Synthesis method of calmodulin inhibitor for treating brain-derived diseases

The invention discloses a synthesis method of a calmodulin inhibitor for treating brain-derived diseases and belongs to the technical field of synthesis of chemicals. The technical scheme is characterized in that a synthetic route of the synthesis method

Structure-Activity Relationships, Pharmacokinetics, and in Vivo Activity of CYP11B2 and CYP11B1 Inhibitors

CYP11B2, the aldosterone synthase, and CYP11B1, the cortisol synthase, are two highly homologous enzymes implicated in a range of cardiovascular and metabolic diseases. We have previously reported the discovery of LCI699, a dual CYP11B2 and CYP11B1 inhibi

Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for the Treatment of Respiratory Disease

The invention relates to substituted diphenylethers, -amines, -sulfides, and -methanes as useful pharmaceutical compounds for treating respiratory-disorders, pharmaceutical compositions containing them, and processes for their preparation.

ORGANIC COMPOUNDS

The present invention provides a compound of formula (I):said compound is inhibitor of aldosterone synthase, and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase. Accordingly, the compound of formula I can be used in treatment of hypokalemia, hypertension, congestive heart failure, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, increased formation of collagen, cardiac fibrosis and remodeling following hypertension and endothelial dysfunction. Finally, the present invention also provides a pharmaceutical composition.

Design and synthesis of piperidine farnesyltransferase inhibitors with reduced glucuronidation potential

The design and synthesis of a novel piperidine series of farnesyltransferase (FTase) inhibitors with reduced potential for metabolic glucuronidation are described. The various substitution and exchange of the phenyl group at the C-2 position of the previously described 2-(4-hydroxy)phenyl-3-nitropiperidine 1a (FTase IC50 = 5.4 nM) resulted in metabolically stable compounds with potent FTase inhibition (14a IC50 = 4.3 nM, 20a IC50 = 3.0 nM, and 50a IC50 = 16 nM). Molecular modeling studies of these compounds complexed with FTase and farnesyl pyrophosphate are also described.